Revenue
No reported data
First Tracks Biotherapeutics, Inc. (TRAX)
Price—Loading quote
Net income
Q1.25
Q2.25
Q1.26
Q2.26
Free cash flow
Q1.25
Q2.25
Q1.26
Q2.26
Total cash / debt
CashTotal debt
Q1.25
Q1.26
Q2.26
Financial statements
| Q2.26 | Q1.26 | Q2.25 | Q1.25 | |
|---|---|---|---|---|
| Research & development | $25.6M | $34.0M | $39.3M | $41.5M |
| Operating expenses | $34.9M | $52.8M | $45.9M | $51.3M |
| Operating income | −$34.9M | −$52.8M | −$45.9M | −$51.3M |
| EBITDAderived | −$34.8M | −$52.7M | −$45.8M | −$51.1M |
| Net income | −$33.4M | −$50.5M | −$42.4M | −$47.2M |
| Basic EPSper diluted share | -$0.95 | — | -$1.47 | — |
| Diluted EPSper diluted share | -$0.95 | — | -$1.47 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 20, 2026Form 4 | EcoR1 Capital, LLCTenPercentOwner | SellCommon Stock · indirect | 4.71M | $13.81 | $64.98M | 3.17M |